BioNTech announced it will not advance a cancer vaccine program in late‑stage melanoma, according to reporting from Endpoints News at ESMO. The company said it remains undecided about studying the candidate in earlier‑stage settings but will pause further development in advanced disease. The move reflects a reassessment of the vaccine’s risk‑benefit profile in refractory melanoma cohorts and underscores the challenges of translating personalized cancer vaccine platforms into late‑line approvals. BioNTech will evaluate next steps based on ongoing data and strategic priorities.